Infectious Disease Billing Companies in California

J0696 is a HCPCS code associated with a drug product, but the correct billing approach depends on the actual product, dose, units, payer requirements, documentation, and whether the claim is processed under a medical or pharmacy benefit. Practices should reconcile the drug charge with administration, diagnosis, medical-necessity documentation, and applicable payer instructions rather than relying on a universal billing pattern.

There is no single reimbursement rate that applies to every J0696 claim. Payment can vary by payer, contract, locality, fee schedule, units, billing circumstances, and whether the claim meets documentation and coverage requirements. GrowInfectiousDisease does not publish invented payment rates. Practices should compare their contracts, payer policies, remittance data, and correctly billed units when evaluating reimbursement.

Support can include claims management, coding review, claim scrubbing, rejection clearing, denial categorization, appeals, eligibility and authorization work, payment reconciliation, A/R follow-up, payer contract review, credentialing, and revenue-cycle consulting. The appropriate scope depends on whether a practice needs ongoing operational support, targeted analysis, overflow assistance, or a prioritized plan to address revenue leakage.

Revenue leakage may arise from under-leveled visits, uncaptured drug or administration charges, documentation gaps, authorization problems, contract issues, unpursued balances, or payment mismatches. A useful review traces the issue to its source across clinical documentation, charge capture, coding, payer rules, and collections. Reporting by payer, service line, and provider can help identify recurring patterns.

Infusion and OPAT workflows may involve drug acquisition, administration, eligibility, authorization, medical or pharmacy benefit decisions, clinical documentation, and payer-specific requirements. These elements must align before the practice can assess whether charges and payments reflect the work performed. Reviewing the full workflow from referral to final payment can expose delays, denials, and unreconciled balances.

Yes. A payment reconciliation review can compare remittance results with expected reimbursement for drug, administration, and E/M claims. It may identify short-pays, incorrect fee schedule application, unit or NDC mismatches, and other discrepancies. Any dispute should be supported by the applicable contract terms, payer policy, claim details, and documentation available to the practice.

No. Workflows differ according to services, providers, payer participation, infusion activity, OPAT operations, hospital arrangements, documentation practices, and internal staffing. A practice may need credentialing, authorization support, claims assistance, denial work, A/R recovery, or broader workflow consulting. Reviewing the actual referral-to-payment process is more useful than applying a generic benchmark.

Look for demonstrated understanding of infectious disease operations, including cognitive services, infusion, OPAT, drug and administration billing, payer contracts, authorizations, denials, and A/R. The provider should explain what is verified, what depends on the practice, and how findings will be tracked. Transparent reporting and practical recommendations are important when evaluating financial sustainability.